Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cyclo-oxygenase-2-specific inhibitors and cardiovascular morbidity.

× No keyword cloud information.

25 in total

Review 1. Renal effects of COX-2-selective inhibitors.

Authors: D C Brater; C Harris; J S Redfern; B J Gertz
Journal: Am J Nephrol Date: 2001 Jan-Feb Impact factor: 3.754

2. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.

Authors: A Van Hecken; J I Schwartz; M Depré; I De Lepeleire; A Dallob; W Tanaka; K Wynants; A Buntinx; J Arnout; P H Wong; D L Ebel; B J Gertz; P J De Schepper
Journal: J Clin Pharmacol Date: 2000-10 Impact factor: 3.126

Review 3. Epidemiology of NSAID induced gastrointestinal complications.

Authors: G Singh; G Triadafilopoulos
Journal: J Rheumatol Suppl Date: 1999-04

4. Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis.

Authors: E A Knijff-Dutmer; A Martens; M A vd Laar
Journal: Ann Rheum Dis Date: 1999-04 Impact factor: 19.103

5. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Authors: M A Konstam; M R Weir; A Reicin; D Shapiro; R S Sperling; E Barr; B J Gertz
Journal: Circulation Date: 2001-11-06 Impact factor: 29.690

6. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.

Authors: E W Ehrich; T J Schnitzer; H McIlwain; R Levy; F Wolfe; M Weisman; Q Zeng; B Morrison; J Bolognese; B Seidenberg; B J Gertz
Journal: J Rheumatol Date: 1999-11 Impact factor: 4.666

7. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors: F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal: JAMA Date: 2000-09-13 Impact factor: 56.272

8. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.

Authors: J Y Fu; J L Masferrer; K Seibert; A Raz; P Needleman
Journal: J Biol Chem Date: 1990-10-05 Impact factor: 5.157

9. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset.

Authors: S Wållberg-Jonsson; H Johansson; M L Ohman; S Rantapää-Dahlqvist
Journal: J Rheumatol Date: 1999-12 Impact factor: 4.666

10. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors:
Journal: BMJ Date: 1994-01-08